356 related articles for article (PubMed ID: 18541621)
1. Design and validation of specific inhibitors of 17beta-hydroxysteroid dehydrogenases for therapeutic application in breast and prostate cancer, and in endometriosis.
Day JM; Tutill HJ; Purohit A; Reed MJ
Endocr Relat Cancer; 2008 Sep; 15(3):665-92. PubMed ID: 18541621
[TBL] [Abstract][Full Text] [Related]
2. 17ß-hydroxysteroid dehydrogenase inhibitors.
Day JM; Tutill HJ; Purohit A
Minerva Endocrinol; 2010 Jun; 35(2):87-108. PubMed ID: 20595938
[TBL] [Abstract][Full Text] [Related]
3. Development of hormone-dependent prostate cancer models for the evaluation of inhibitors of 17beta-hydroxysteroid dehydrogenase type 3.
Day JM; Tutill HJ; Foster PA; Bailey HV; Heaton WB; Sharland CM; Vicker N; Potter BV; Purohit A; Reed MJ
Mol Cell Endocrinol; 2009 Mar; 301(1-2):251-8. PubMed ID: 18786604
[TBL] [Abstract][Full Text] [Related]
4. 17β-Hydroxysteroid dehydrogenases (17β-HSDs) as therapeutic targets: protein structures, functions, and recent progress in inhibitor development.
Marchais-Oberwinkler S; Henn C; Möller G; Klein T; Negri M; Oster A; Spadaro A; Werth R; Wetzel M; Xu K; Frotscher M; Hartmann RW; Adamski J
J Steroid Biochem Mol Biol; 2011 May; 125(1-2):66-82. PubMed ID: 21193039
[TBL] [Abstract][Full Text] [Related]
5. Structural basis of the multispecificity demonstrated by 17beta-hydroxysteroid dehydrogenase types 1 and 5.
Lin SX; Shi R; Qiu W; Azzi A; Zhu DW; Dabbagh HA; Zhou M
Mol Cell Endocrinol; 2006 Mar; 248(1-2):38-46. PubMed ID: 16480815
[TBL] [Abstract][Full Text] [Related]
6. Steroid metabolism in breast cancer.
Foster PA
Minerva Endocrinol; 2008 Mar; 33(1):27-37. PubMed ID: 18277377
[TBL] [Abstract][Full Text] [Related]
7. Perspectives in understanding the role of human 17beta-hydroxysteroid dehydrogenases in health and disease.
Meier M; Möller G; Adamski J
Ann N Y Acad Sci; 2009 Feb; 1155():15-24. PubMed ID: 19250188
[TBL] [Abstract][Full Text] [Related]
8. Modification of estrone at the 6, 16, and 17 positions: novel potent inhibitors of 17beta-hydroxysteroid dehydrogenase type 1.
Allan GM; Lawrence HR; Cornet J; Bubert C; Fischer DS; Vicker N; Smith A; Tutill HJ; Purohit A; Day JM; Mahon MF; Reed MJ; Potter BV
J Med Chem; 2006 Feb; 49(4):1325-45. PubMed ID: 16480268
[TBL] [Abstract][Full Text] [Related]
9. 17beta-hydroxysteroid dehydrogenases in human breast cancer.
Nagasaki S; Miki Y; Akahira J; Suzuki T; Sasano H
Ann N Y Acad Sci; 2009 Feb; 1155():25-32. PubMed ID: 19250189
[TBL] [Abstract][Full Text] [Related]
10. 17beta-Hydroxysteroid dehydrogenase inhibitors: a patent review.
Poirier D
Expert Opin Ther Pat; 2010 Sep; 20(9):1123-45. PubMed ID: 20645882
[TBL] [Abstract][Full Text] [Related]
11. Synthesis and biological evaluation of 17beta-hydroxysteroid dehydrogenase type 1 (17beta-HSD1) inhibitors based on a thieno[2,3-d]pyrimidin-4(3H)-one core.
Lilienkampf A; Karkola S; Alho-Richmond S; Koskimies P; Johansson N; Huhtinen K; Vihko K; Wähälä K
J Med Chem; 2009 Nov; 52(21):6660-71. PubMed ID: 19824648
[TBL] [Abstract][Full Text] [Related]
12. Reductive 17beta-hydroxysteroid dehydrogenases in the sulfatase pathway: critical in the cell proliferation of breast cancer.
Aka JA; Mazumdar M; Lin SX
Mol Cell Endocrinol; 2009 Mar; 301(1-2):183-90. PubMed ID: 19038308
[TBL] [Abstract][Full Text] [Related]
13. Cinnamates and cinnamamides inhibit fungal 17beta-hydroxysteroid dehydrogenase.
Kristan K; Starcević S; Brunskole M; Rizner TL; Gobec S
Mol Cell Endocrinol; 2006 Mar; 248(1-2):239-41. PubMed ID: 16337334
[TBL] [Abstract][Full Text] [Related]
14. STX2171, a 17β-hydroxysteroid dehydrogenase type 3 inhibitor, is efficacious in vivo in a novel hormone-dependent prostate cancer model.
Day JM; Foster PA; Tutill HJ; Schmidlin F; Sharland CM; Hargrave JD; Vicker N; Potter BV; Reed MJ; Purohit A
Endocr Relat Cancer; 2013 Feb; 20(1):53-64. PubMed ID: 23132791
[TBL] [Abstract][Full Text] [Related]
15. Development of a biological screening system for the evaluation of highly active and selective 17beta-HSD1-inhibitors as potential therapeutic agents.
Kruchten P; Werth R; Marchais-Oberwinkler S; Frotscher M; Hartmann RW
Mol Cell Endocrinol; 2009 Mar; 301(1-2):154-7. PubMed ID: 18984028
[TBL] [Abstract][Full Text] [Related]
16. Multifunctionality of human 17beta-hydroxysteroid dehydrogenases.
Moeller G; Adamski J
Mol Cell Endocrinol; 2006 Mar; 248(1-2):47-55. PubMed ID: 16413960
[TBL] [Abstract][Full Text] [Related]
17. Design, synthesis, and biological evaluation of (hydroxyphenyl)naphthalene and -quinoline derivatives: potent and selective nonsteroidal inhibitors of 17beta-hydroxysteroid dehydrogenase type 1 (17beta-HSD1) for the treatment of estrogen-dependent diseases.
Frotscher M; Ziegler E; Marchais-Oberwinkler S; Kruchten P; Neugebauer A; Fetzer L; Scherer C; Müller-Vieira U; Messinger J; Thole H; Hartmann RW
J Med Chem; 2008 Apr; 51(7):2158-69. PubMed ID: 18324762
[TBL] [Abstract][Full Text] [Related]
18. Inhibitors of 17 beta-hydroxysteroid dehydrogenases.
Poirier D
Curr Med Chem; 2003 Mar; 10(6):453-77. PubMed ID: 12570693
[TBL] [Abstract][Full Text] [Related]
19. Dydrogesterone (Duphaston) and its 20-dihydro-derivative as selective estrogen enzyme modulators in human breast cancer cell lines. Effect on sulfatase and on 17beta-hydroxysteroid dehydrogenase (17beta-HSD) activity.
Chetrite GS; Thole HH; Philippe JC; Pasqualini JR
Anticancer Res; 2004; 24(3a):1433-8. PubMed ID: 15274306
[TBL] [Abstract][Full Text] [Related]
20. Expression of 17beta-hydroxysteroid dehydrogenases and other estrogen-metabolizing enzymes in different cancer cell lines.
Smuc T; Rizner TL
Chem Biol Interact; 2009 Mar; 178(1-3):228-33. PubMed ID: 19022235
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
